ROMA (ITALPRESS) – Angelini Pharma, part of Angelini Industries – Italian multinational group active in the fields of health, industrial technology and consumption – announced the appointment of Sergio Marullo di Condojanni to Chief Executive Officer. Marullo di Condojanni has served as CEO of Angelini Industries since 2020 and will continue to play this role, taking the lead of the pharmaceutical division at the same time to promote the implementation of a coherent and integrated strategy, enhancing its extensive experience in management, governance and finance. Jacopo Andreose, who led Angelini Pharma until the end of 2025, will join the Board of Directors of Angelini Holding and will become senior advisor of the Board of Directors of Angelini Pharma.
“The appointment of Sergio to CEO will simplify the decision-making process of our pharmaceutical division, the heart of our Group. This strategic choice will allow us to be closer to the needs of the market and, above all, to patients, ensuring greater efficiency, agility, rapid decision making and flexibility”, said Thea Paola Angelini, President of Angelini Holding.
Marullo di Condojanni’s dual assignment will allow him to direct the implementation of the strategy within the healthcare division, with the aim of maximizing the value of Angelini Pharma in a high-growth sector, while at the same time promoting more effective strategic alignment and greater decision-making timeliness. The focus will be on strengthening the leadership of the group in the Brain Health, in particular in the field of rare neurological diseases, continuing parallel in the development of the Consumer Healthcare business. Among other priorities, the expansion of the global presence of Angelini Pharma, also through new acquisitions aimed at strengthening the pipeline of innovative drugs and promising candidates. The commitment to support investments in research, development and production in Italy remains central, flanked by a strategy of openness to international markets to seize further growth opportunities.
“I am thrilled and deeply honored to take this important assignment to lead Angelini Pharma in a crucial phase of transformation – said Sergio Marullo di Condojanni –. Our strategic priorities are clear: strengthening the long-term competitiveness and seizing opportunities of transformative M&A that allow us to grow globally. At the same time, we will continue to implement an ambitious strategy aimed at achieving market leadership and developing innovative and disruptive solutions in brain health for the benefit of patients all over the world.” “The new strategic vision will be supported by a renewed organizational structure, based on dedicated franchises, with the aim of maximizing value creation and supporting international expansion in areas with higher growth potential”, reads in a note.
– photo office printing Angelini Pharma –
(ITALPRESS).
